xtl logo 88.
(photo credit: )
X
Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before.
Nevertheless, traditional business models are no longer sustainable and high-quality publications,
like ours, are being forced to look for new ways to keep going. Unlike many other news organizations,
we have not put up a paywall. We want to keep our journalism open
and accessible and be able to keep providing you with news
and analyses from the frontlines of Israel, the Middle East and the Jewish World.
As one of our loyal readers, we ask you to be our partner.
For a symbolic $5 a month you will receive access to the following:
- A user uxperience almost completely free of ads
- Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
- Content from the award-winning Jerusalem Repor
- A brand new ePaper featuring the daily newspaper as it appears in print in Israel
Help us grow and continue telling Israel’s story to the world.
Thank you,
Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief
UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH
Don't show it again
Rehovot-based XTL Biopharmaceuticals named Ron Bentsur as chief executive, ending an 11-month period without a CEO.
In February, rebel investors persuaded shareholders to oust interim chairman and chief executive Elkan Gamzu and two other directors. XTL appointed Michael Weiss as interim chairman in March and then non-executive chairman in August, but failed to appoint a CEO until now.
XTL said on Tuesday that Bentsur comes from US company Keryx Biopharmaceuticals, where he is vice president for finance and investor relations, a job he will continue to carry out for a transitional period.